AU2009204084A1 - Intrathecal treatment of neuropathic pain with A2AR agonists - Google Patents

Intrathecal treatment of neuropathic pain with A2AR agonists Download PDF

Info

Publication number
AU2009204084A1
AU2009204084A1 AU2009204084A AU2009204084A AU2009204084A1 AU 2009204084 A1 AU2009204084 A1 AU 2009204084A1 AU 2009204084 A AU2009204084 A AU 2009204084A AU 2009204084 A AU2009204084 A AU 2009204084A AU 2009204084 A1 AU2009204084 A1 AU 2009204084A1
Authority
AU
Australia
Prior art keywords
alkyl
alkylene
aryl
heteroaryl
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009204084A
Other languages
English (en)
Inventor
Anthony Beauglehole
Mark Hutchinson
Lisa Loram
Jayson Rieger
Frank Schmidtmann
Robert Thompson
Linda Watkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trovis Pharmaceuticals LLC
Original Assignee
Trovis Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trovis Pharmaceuticals LLC filed Critical Trovis Pharmaceuticals LLC
Publication of AU2009204084A1 publication Critical patent/AU2009204084A1/en
Assigned to TROVIS PHARMACEUTICALS LLC reassignment TROVIS PHARMACEUTICALS LLC Amend patent request/document other than specification (104) Assignors: PGXHEALTH, LLC
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AU2009204084A 2008-01-09 2009-01-09 Intrathecal treatment of neuropathic pain with A2AR agonists Abandoned AU2009204084A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1991208P 2008-01-09 2008-01-09
US61/019,912 2008-01-09
PCT/US2009/030565 WO2009089425A1 (en) 2008-01-09 2009-01-09 Intrathecal treatment of neuropathic pain with a2ar agonists

Publications (1)

Publication Number Publication Date
AU2009204084A1 true AU2009204084A1 (en) 2009-07-16

Family

ID=40851205

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009204084A Abandoned AU2009204084A1 (en) 2008-01-09 2009-01-09 Intrathecal treatment of neuropathic pain with A2AR agonists

Country Status (10)

Country Link
US (1) US20090181920A1 (enExample)
EP (1) EP2240020A4 (enExample)
JP (1) JP2011509305A (enExample)
CN (1) CN101938904A (enExample)
AU (1) AU2009204084A1 (enExample)
BR (1) BRPI0907248A2 (enExample)
CA (1) CA2711495A1 (enExample)
EA (1) EA201001135A1 (enExample)
IL (1) IL206801A0 (enExample)
WO (1) WO2009089425A1 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG176313A1 (en) * 2001-10-01 2011-12-29 Univ Virginia Patent Found 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
US8178509B2 (en) * 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
EA200870409A1 (ru) 2006-04-04 2009-04-28 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Антагонисты киназы pi3
ATE549337T1 (de) 2006-04-21 2012-03-15 Novartis Ag Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
ES2361886T3 (es) * 2006-06-27 2011-06-24 Cbt Development Limited Profármacos adenosina acetil 2',3'-metilideno novedosos para uso como profármacos para agonistas del receptor adenosina.
EP1889846A1 (en) * 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
US7985754B2 (en) * 2006-07-17 2011-07-26 Trovis Pharmaceuticals, Llc Selective antagonists of A2A adenosine receptors
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
JP2010508835A (ja) * 2006-11-10 2010-03-25 ノバルティス アーゲー シクロペンテンジオールモノアセテート誘導体
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CA2711558C (en) 2008-01-04 2016-12-13 Intellikine, Inc. Phosphatidyl inositol-3 kinase inhibiting compounds
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
AU2009268611B2 (en) 2008-07-08 2015-04-09 Intellikine, Llc Kinase inhibitors and methods of use
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
CA2740885C (en) 2008-10-16 2018-04-03 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
WO2011143442A1 (en) * 2010-05-12 2011-11-17 Trovis Pharmaceuticals, Llc. A method of treating multiple sclerosis with adenosine receptor agonists
AU2011255218B2 (en) 2010-05-21 2015-03-12 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
EP2608794A4 (en) * 2010-08-26 2014-01-22 Univ Northeastern METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING OIL CONTAINER
JP5921555B2 (ja) 2010-09-29 2016-05-24 エスケー バイオファーマシューティカルズ カンパニー リミテッド 新規メチルシクロヘキサン誘導体およびその使用
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
JP5931905B2 (ja) 2010-12-03 2016-06-08 エピザイム，インコーポレイティド 置換プリン及び７‐デアザプリン化合物
AU2011336272A1 (en) 2010-12-03 2013-06-20 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
AU2012205669B2 (en) 2011-01-10 2015-08-20 Infinity Pharmaceuticals Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
JP6130305B2 (ja) 2011-02-23 2017-05-17 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
US9132131B2 (en) 2011-04-21 2015-09-15 Saint Louis University Use of adenosine A3 receptor agonists for treatment of neuropathic pain
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6027610B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
EP2751093A1 (en) 2011-08-29 2014-07-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
CN104363757B (zh) * 2012-02-11 2017-05-24 中央研究院 治疗疼痛的方法及组合物
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014026198A1 (en) 2012-08-10 2014-02-13 Epizyme, Inc. Inhibitors of protein methyltransferase dot1l and methods of use thereof
CA2883781A1 (en) 2012-09-06 2014-03-13 Epizyme, Inc. Method of treating leukemia
MX2015003874A (es) 2012-09-26 2015-12-16 Univ California Modulacion de ire1.
KR102229478B1 (ko) 2012-11-01 2021-03-18 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
EP2968387A4 (en) 2013-03-15 2017-04-05 Epizyme, Inc. Methods of synthesizing substituted purine compounds
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20160685A1 (es) 2013-10-04 2016-07-23 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2017160930A1 (en) * 2016-03-16 2017-09-21 Kalyra Pharmaceuticals, Inc. Analgesic compounds
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX391135B (es) 2016-06-24 2025-03-21 Infinity Pharmaceuticals Inc Terapias de combinacion.
WO2018035380A1 (en) 2016-08-17 2018-02-22 Solstice Biologics, Ltd. Polynucleotide constructs
WO2019006455A1 (en) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801188A (en) * 1997-01-08 1998-09-01 Medtronic Inc. Clonidine therapy enhancement
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
SG176313A1 (en) * 2001-10-01 2011-12-29 Univ Virginia Patent Found 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
GB0228723D0 (en) * 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
US7261882B2 (en) * 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
US20050004221A1 (en) * 2003-07-01 2005-01-06 Medtronic, Inc. Intrathecal gabapentin compositions
MXPA06010075A (es) * 2004-03-05 2007-04-10 Cambridge Biotechnology Ltd Compuestos terapeuticos.
GB0405009D0 (en) * 2004-03-05 2004-04-07 Cambridge Biotechnology Ltd Analgesics
CA2576826C (en) * 2004-08-02 2014-09-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
US7589076B2 (en) * 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury

Also Published As

Publication number Publication date
IL206801A0 (en) 2010-12-30
JP2011509305A (ja) 2011-03-24
EA201001135A1 (ru) 2011-02-28
EP2240020A1 (en) 2010-10-20
CA2711495A1 (en) 2009-07-16
CN101938904A (zh) 2011-01-05
US20090181920A1 (en) 2009-07-16
BRPI0907248A2 (pt) 2019-02-26
EP2240020A4 (en) 2011-05-11
WO2009089425A1 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
CA2711495A1 (en) Intrathecal treatment of neuropathic pain with a2ar agonists
CA2384111C (en) Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US8178509B2 (en) Method to treat sickle cell disease
US7396825B2 (en) Agonists of A2A adenosine receptors for treatment of diabetic nephropathy
US7427606B2 (en) Method to reduce inflammatory response in transplanted tissue
US8551972B2 (en) Agonists of A2A adenosine receptors for treating recurrent tumor growth
WO2007092936A2 (en) Method to treat gastric lesions
AU1292095A (en) Purine compositions and methods for administration
CN113056272A (zh) 新的喹唑啉egfr抑制剂
JP2009530295A5 (enExample)
US8349792B2 (en) Combination comprising CNDAC (2′-cyano-2′-deoxy-N4-palmitoyl-1-beta-D-arabinofuranosyl-cytosine) and a cytotoxic agent
PT2754441E (pt) Composição para a prevenção e tratamento de cancro do pulmão de não pequenas células, contendo derivados de pirazino-triazina
JP5317987B2 (ja) 白血病の治療のための新規な治療のための使用
CA2191230C (en) 2-halo-2'-deoxyadenosine treatment for inflammatory bowel disease
HK1152836A (en) Intrathecal treatment of neuropathic pain with a2ar agonists
AU735319B2 (en) 2-halo-2'-deoxyadenosine treatment for inflammatory bowel disease
WO2011143442A1 (en) A method of treating multiple sclerosis with adenosine receptor agonists
CN117982636A (zh) 一种预防和/或治疗脑胶质瘤的联合用药组合产品以及联合制药用途
AU2001292591A1 (en) Purine ribosides as antiarrhythmics
WO2007000771A2 (en) Fused quinazolinone derivatives and uses thereof
HK1118707A (en) Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application